RareResearch.AI
← Back to atlas

A48V

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedSource card
AlanineValine at position 48 · N-term IDR (1-86) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type A48 — native residue, no strong sidechain contacts
Fullscreen ↗
DynaMut2 mutant · A48V
Mutant V48 — energy-minimized; local contact network preserved
Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG
-0.75kcal/mol
Destabilising_but_UNTRUSTED_IDR — mild
AlphaMissense
0.075
LBen
AlphaFold pLDDT
25
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 25.08 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsInborn genetic diseases; not specified; not provided
Population frequency (gnomAD v4)Ultra-rare · AF 0.00076%
cDNA changec.143C>T
ClinVar accessionVCV000045435
Last evaluated2025/12/20 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity, but does not state what it is classified for. ClinVar records the condition only as "Inborn genetic diseases", "not specified", "not provided". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.00076% · 12 / 1,575,320 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.0010%

Highest in European (non-Finnish): AF 0.0010% (12 of 1,160,602 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.0010%12 / 1,160,6020~1 in 48360

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — A48V Variant Card

Molecular Atlas Pilot Variant · RareResearch.AI · Windsor Symposium Demo

Prepared: May 26, 2026 · Schema target: Category 5 — IDR EXCLUSION


Identity

FieldValue
VariantA48V
DNA changec.143C>T
GeneWFS1
ProteinWolframin (890 aa)
UniProt IDO76024
ClinVar accessionVCV000045435
Amino acid changeA → V at position 48

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 4825.08
DomainN-terminal intrinsically disordered region (1-86)
UniProt features at this position
  • Chain: 1-890 Wolframin
  • Region: 1-321 Interaction with ATP6V1A
  • Region: 1-86 Disordered

Position 48, pLDDT 25.08. This residue belongs to wolframin's disordered N-terminal region (residues 1–86), annotated by UniProt as the ATP6V1A interaction region but lacking defined secondary structure. AlphaFold's confidence is below the IDR threshold of 50 — meaning the model is essentially a guess about local geometry.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.0750
am_classLBen
InterpretationLikely benign per AlphaMissense

DynaMut2

FieldValue
Job ID177985960542
ΔΔG (kcal/mol)-0.75 kcal/mol (Destabilising)
Result URLJob 177985960542 · retrieved 2026-05-27 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Conflicting classifications of pathogenicity — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Conflicting classifications of pathogenicity, but does not state what it is classified for. ClinVar records the condition only as "Inborn genetic diseases", "not specified", "not provided". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Last evaluated2025/12/20 00:00
Associated conditionsInborn genetic diseases; not specified; not provided; Wolfram syndrome 1

Computational vs Clinical Tension

AlphaMissense 0.075 (LBen — Likely Benign). ClinVar shows Conflicting classifications of pathogenicity — submitting labs cannot agree. Some call it Wolfram syndrome 1; others call it benign. The Atlas resolves this tension by refusing to take a structural position: in an IDR, structure-based predictions are unreliable, and the variant must be triaged to wet-lab functional validation (cell-based assays, family segregation, RNA effects).


Phenotype focus

Reported in Wolfram syndrome 1 by some submitters; benign by others — clinical signal unresolved

Carrier story

A48V is a litmus test for the Atlas's intellectual honesty. It sits at position 48 in the N-terminal intrinsically disordered region, pLDDT 25.08 — deep in the floppy zone where no static model can support reliable structure-function inference.

Mechanism hypothesis

If DynaMut2 returns any specific ΔΔG, that value is not trustworthy for a low-pLDDT residue — DynaMut2 assumes a meaningful starting structure. The correct schema output for A48V is Category 5 — exclude from druggability prediction; flag for experimental validation only. This is the Atlas saying 'I don't know — and here's why.'


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • A48V_molstar_viewer.html — interactive 3D viewer (auto-loads and highlights position 48)
  • A48V_variant_card.md — this card
  • A48V_variant_card.html — demo-ready styled version

Final Schema Categorization

Category 5 — IDR EXCLUSION (DynaMut2 result is NOT trustworthy)

DynaMut2 returned a routine-looking -0.75 kcal/mol. That number should not be used clinically. The starting AlphaFold structure at position 48 has pLDDT 25.08 — well below the 50 threshold below which the model's local geometry is essentially noise. DynaMut2 assumes a meaningful input structure; for IDR residues that assumption is violated. Combined with AlphaMissense 0.075 (benign) and ClinVar's Conflicting clinical classifications, A48V is the Atlas's textbook 'I don't know — route to wet-lab' case. The schema's intellectual honesty matters most here.


Every assumption documented. Every score sourced. The Atlas standard.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A48V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A48V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.